PNC Financial Services Group Inc. Reduces Holdings in Becton, Dickinson and Company $BDX

PNC Financial Services Group Inc. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 173,878 shares of the medical instruments supplier’s stock after selling 2,876 shares during the period. PNC Financial Services Group Inc. owned approximately 0.06% of Becton, Dickinson and Company worth $32,545,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in BDX. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Empowered Funds LLC grew its stake in shares of Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after buying an additional 1,354 shares during the last quarter. Stratos Wealth Partners LTD. raised its holdings in shares of Becton, Dickinson and Company by 0.5% in the second quarter. Stratos Wealth Partners LTD. now owns 16,040 shares of the medical instruments supplier’s stock worth $2,763,000 after buying an additional 81 shares during the period. United Bank lifted its stake in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after acquiring an additional 993 shares during the last quarter. Finally, Chicago Partners Investment Group LLC lifted its stake in shares of Becton, Dickinson and Company by 15.3% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 1,807 shares of the medical instruments supplier’s stock worth $330,000 after acquiring an additional 240 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Barclays started coverage on Becton, Dickinson and Company in a research note on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 target price on the stock. Zacks Research cut shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th. Citigroup reduced their price target on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Finally, TD Cowen raised their target price on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Stock Down 1.0%

NYSE:BDX opened at $175.95 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $185.02. The company has a 50-day moving average of $198.55 and a 200 day moving average of $192.32. The firm has a market cap of $50.10 billion, a PE ratio of 28.70, a price-to-earnings-growth ratio of 2.30 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter last year, the firm posted $3.43 EPS. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company declared that its board has initiated a stock repurchase plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 2,463 shares of company stock worth $501,530 in the last ninety days. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.